A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

By reducing inflammation, the researchers were able to prevent both the buildup of immune cells and the formation of these ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

For just a few hours, shimmering waves of calcium move through cells in the developing eyes of fruit flies. These spontaneous waves serve a purpose, enabling communication between cells and shaping ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

Older age in adults with diabetic macular edema (DME) appears to be associated with less robust visual and anatomic gains from anti-vascular endothelial growth factor (VEGF) therapy, according to ...